Rate My Professor Jamie Triccas

With more than 30 years of experience in bacteriology, Professor Triccas utilizes a multidisciplinary approach to elucidate immunity to chronic bacterial pathogens such as Mycobacterium tuberculosis and Methicillin-resistant Staphylococcus aureus. His academic interests center on bacterial pathogenesis, T cell immune responses to virulent lung pathogens, and the development of novel tuberculosis vaccines, drugs, and adjuvants. He is Principal Investigator for the National Institutes of Health-funded Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) contract, a five-year program to identify promising adjuvant-TB immunogen candidates for clinical development and define immune correlates of protection. Additionally, he leads a CEPI-supported consortium with ExcellGene and Bharat Biotech to develop a broadly protective SARS-CoV-2 vaccine, and his group has advanced TB and COVID-19 vaccine candidates toward clinical trials. Triccas has authored over 128 peer-reviewed publications, accumulating more than 10,000 citations. Key publications include "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection" (2021, 4369 citations), "Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis" (2022, 660 citations), "Analysis of the Phthiocerol Dimycocerosate Locus of Mycobacterium tuberculosis: Evidence that this lipid is involved in the cell wall permeability barrier" (2001, 489 citations), "Cutaneous immunosurveillance by self-renewing dermal γδ T cells" (2011, 336 citations), and "Migratory dermal dendritic cells act as rapid sensors of protozoan parasites" (2008, 304 citations). His research has significant impact on vaccine development for global infectious diseases, including co-founding Vaxosome to advance TB vaccines.